Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Subacute Inflammatory Demyelinating Polyneuropathy: Not a New Concept-Reply

Subacute Inflammatory Demyelinating Polyneuropathy: Not a New Concept-Reply Abstract in reply I am pleased to acknowledge that Oh discussed the concept of an intermediate form of neuropathy between Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy in 1978 in the light of concepts then current in an article that we would have been pleased to quote if we had been aware of its existence. However, I find Oh's response confusing, since he appears to equate subacute demyelinating neuropathy with CIDP in the first sentence of his penultimate paragraph, and the modern definition of CIDP would classify nine of his 10 patients as having CIDP and not SIDP (subacute idiopathic demyelinating polyradiculopathy). Since we now have definitions of Guillain-Barré syndrome reaching its nadir within 4 weeks and CIDP reaching its nadir after 2 months (8 weeks would be better) from international committees, I adhere to the view that only the intermediate group should be considered to have SIDP. If patients with References 1. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome . Lancet . 1993;341:586-590. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

Subacute Inflammatory Demyelinating Polyneuropathy: Not a New Concept-Reply

Hughes, Richard
Archives of Neurology , Volume 51 (3) – Mar 1, 1994
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/subacute-inflammatory-demyelinating-polyneuropathy-not-a-new-concept-DpwZQ0u3kL

References (1)

Publisher
American Medical Association
Copyright
Copyright © 1994 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.1994.00540150020009
Publisher site
See Article on Publisher Site

Abstract

Abstract in reply I am pleased to acknowledge that Oh discussed the concept of an intermediate form of neuropathy between Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy in 1978 in the light of concepts then current in an article that we would have been pleased to quote if we had been aware of its existence. However, I find Oh's response confusing, since he appears to equate subacute demyelinating neuropathy with CIDP in the first sentence of his penultimate paragraph, and the modern definition of CIDP would classify nine of his 10 patients as having CIDP and not SIDP (subacute idiopathic demyelinating polyradiculopathy). Since we now have definitions of Guillain-Barré syndrome reaching its nadir within 4 weeks and CIDP reaching its nadir after 2 months (8 weeks would be better) from international committees, I adhere to the view that only the intermediate group should be considered to have SIDP. If patients with References 1. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome . Lancet . 1993;341:586-590.

Journal

Archives of Neurology – American Medical Association

Published: Mar 1, 1994

There are no references for this article.